1. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG;Abecasis;Antivir. Ther.,2006
2. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G;Abecasis;AIDS,2005
3. Recombination confounds the early evolutionary history of human immunodeficiency virus type 1: subtype G is a circulating recombinant form;Abecasis;J. Virol.,2007
4. Abecasis, A.B., Wensing, A.M.J., Vercauteren, J., Paraskevis, D., van de Vijver, D.A., Albert, J., Asjo, B., Balotta, C., Bruckova, M., Camacho, R., Coughlan, S., Grossman, Z., Hamouda, O., Hatzakis, A., Horban, A., Korn, K., Kostrikis, L., Kücherer, C., Nielsen, C., Poljak, M., Puchhammer-Stockl, E., Riva, C., Ruiz, L., Salminen, M., Schmit, J.C., Schuurman, R., Sonnerborg, A., Stanekova, D., Stanojevic, M., Struck, D., Boucher, C.A.B., Vandamme, A.M., on behalf of the SPREAD-programme, 2008. Demographic determinants of HIV-1 subtype distribution in Europe. In: 6th European HIV Drug Resistance Workshop.
5. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads;Baeten;J. Infect. Dis.,2007